Article citationsMore>>

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J.M., et al. (2012) Erlotinib Versus Standard Chemotherapy as First-line Treatment for European Patients with Advanced EGFR Mutation-positive Non-small-cell Lung Cancer (EURTAC): A Multicentre, Open-label, Randomised Phase 3 Trial. The Lancet Oncology, 13, 239-246.
https://doi.org/10.1016/S1470-2045(11)70393-X

has been cited by the following article:

• TITLE: The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

  AUTHORS: Xiaoshun Shi, Fuxi Huang, Allen M. Chen, Zhuolin Wu, Qianqian Huang, Ying Liang, Qipeng Zhou, Haiyun Mo, Xiaoxiang Li, Jiexia Zhang

  KEYWORDS: EGFR Mutation, Chemotherapy, Non-Small Cell Lung Cancer, Me-ta-Analysis

  JOURNAL NAME: Open Journal of Genetics, Vol.7 No.4, December 21, 2017

  ABSTRACT: Background: Emerging evidence indicates that chemotherapy for lung cancer may alter EGFR mutation status. However, whether chemotherapy as a firstline treatment may increase or reduce the frequency of EGFR mutations in NSCLC remains uncertain. Therefore, we conducted a meta-analysis to evaluate whether chemotherapy leads to altered EGFR mutation status. Methods: A systematic literature search was performed using the PubMed, OVID, Science Direct, Cochrane Library, and CNKI databases for studies on pre- and post-chemotherapy EGFR mutation status. Relevant studies documenting perichemotherapy EGFR mutation ratios were included. Analyses of pooled odds ratios (OR) were performed. Results: Six studies involving 656 patients were included in this meta-analysis. It was found that chemotherapy may alter EGFR status (OR = 1.93, 95% CI 1.05 - 3.56; p Conclusions: Chemotherapy may contribute to altered EGFR status. NSCLC patients with EGFR mutations might need to be considered for EGFR status redeterminations prior to second-line EGFR-TKI treatment or upon tumor recurrence after chemotherapy. Further randomized clinical trials should investigate the impact of neoadjuvant or first-line chemotherapy on EGFR mutation status in NSCLC patients.